Cyron Therapeutics announced that its proprietary AI-based drug discovery platform 'CyronAI' has successfully reduced drug candidate discovery time by 50% compared to traditional methods.
CyronAI is a system that analyzes millions of compound databases and clinical data using deep learning algorithms to predict optimal drug candidates. It can particularly predict drug efficacy, toxicity, and drug interactions in advance, significantly reducing clinical failure rates.
An Alzheimer's treatment candidate developed using CyronAI completed in just 2.5 years what would have taken 5 years with traditional methods, and is currently showing excellent results in preclinical stages.
The company plans to continuously enhance the CyronAI platform and offer it as a service to other pharmaceutical companies, expressing ambitions to contribute to dramatically accelerating global drug development speed.